サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1523027

アイゼンメンジャー症候群治療市場レポート：2030年までの動向、予測、競合分析

Eisenmenger Syndrome Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日
発行
Lucintel
ページ情報
英文 150 Pages
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

アイゼンメンジャー症候群治療市場レポート：2030年までの動向、予測、競合分析
出版日: 2024年07月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アイゼンメンジャー症候群治療の動向と予測

世界のアイゼンメンジャー症候群治療市場は、2024年から2030年にかけてCAGR 5.8％で成長すると予測されます。この市場の主な促進要因は、アイゼンメンジャー症候群に罹患する患者数の増加と、先端薬の開発に関連する研究開発活動への注目の高まりです。世界のアイゼンメンジャー症候群治療市場の将来は、病院薬局、オンライン薬局、小売薬局の各市場における機会によって有望視されています。

セグメント別のアイゼンメンジャー症候群治療

本調査では、世界のアイゼンメンジャー症候群治療薬の薬剤タイプ別、流通チャネル別、地域別の予測を掲載しています。

アイゼンメンジャー症候群治療市場の洞察

Lucintel社の予測では、エンドセリン受容体拮抗薬は、様々な合併症の管理に広く影響し、潜在的に低コストであるため、予測期間中に最も高い成長が見込まれます。

この市場の中では、病院薬局が予測期間中に最も高い成長を遂げると予想されます。

北米は、慢性疾患の増加や先進医療技術の採用率が高いことから、予測期間中も最大地域であり続けるでしょう。

よくある質問

Q1.市場の成長予測は：

A1.世界のアイゼンメンジャー症候群治療市場は、2024年から2030年にかけてCAGR 5.8％で成長すると予測されています。

Q2.市場の成長に影響を与える主な促進要因は：

A2.この市場の主な促進要因は、アイゼンメンジャー症候群に罹患する患者数の増加と、先進医薬品の開発に関連する研究開発活動への注目の高まりです。

Q3.市場の主要セグメントは：

A3.アイゼンメンジャー症候群治療市場の将来性は、病院薬局、オンライン薬局、小売薬局市場での機会により有望視されます。

Q4.市場の主要企業は：

A4.アイゼンメンジャー症候群治療薬の主要企業は以下の通り：

  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Pfizer
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Mylan
  • Bayer

Q5.今後、最大となる市場セグメントは：

A5.Lucintelは、エンドセリン受容体拮抗薬は、様々な合併症の管理に広く影響し、潜在的に低コストであるため、予測期間中に最も高い成長を示すと予測しています。

Q6.市場において、今後5年間に最大になると予想される地域は：

A6.北米は、慢性疾患の増加や先進医療技術の採用率が高いことから、予測期間中も最大地域であり続けると予想されます。

Q7.レポートのカスタマイズは可能か：

A7.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のアイゼンメンジャー症候群治療市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のアイゼンメンジャー症候群治療市場の動向（2018～2023年）と予測（2024～2030年）
  • 薬剤タイプ別のアイゼンメンジャー症候群治療の世界市場
    • 抗不整脈薬
    • 血液凝固阻止薬
    • エンドセリン受容体拮抗薬
    • その他
  • 流通チャネル別のアイゼンメンジャー症候群治療の世界市場
    • 病院薬局
    • オンライン薬局
    • 小売薬局

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別のアイゼンメンジャー症候群治療市場
  • 北米のアイゼンメンジャー症候群治療市場
  • 欧州のアイゼンメンジャー症候群治療市場
  • アジア太平洋地域のアイゼンメンジャー症候群治療市場
  • その他地域のアイゼンメンジャー症候群治療市場

第5章 競合分析

  • 製品ポートフォリオ分析
  • 業務統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
  • 世界のアイゼンメンジャー症候群治療市場の新たな動向
  • 戦略分析
    • 新製品の開発
    • 世界のアイゼンメンジャー症候群治療市場の能力拡大
    • 世界のアイゼンメンジャー症候群治療市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 主要企業の企業プロファイル

  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Pfizer
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Mylan
  • Bayer
目次

Eisenmenger Syndrome Treatment Trends and Forecast

The future of the global eisenmenger syndrome treatment market looks promising with opportunities in the hospital pharmacies, online pharmacies, and retail pharmacies markets. The global eisenmenger syndrome treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are growing number of patients suffering from eisenmenger syndrome and rising focus on r&d activities related to the development of advanced drugs.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Eisenmenger Syndrome Treatment by Segment

The study includes a forecast for the global eisenmenger syndrome treatment by drug type, distribution channel, and region.

Eisenmenger Syndrome Treatment Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Antiarrhythmic Agents
  • Blood Thinning Agents
  • Endothelin Receptor Antagonist
  • Others

Eisenmenger Syndrome Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Eisenmenger Syndrome Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Eisenmenger Syndrome Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies eisenmenger syndrome treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the eisenmenger syndrome treatment companies profiled in this report include-

  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Pfizer
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Mylan
  • Bayer

Eisenmenger Syndrome Treatment Market Insights

Lucintel forecasts that endothelin receptor antagonist is expected to witness the highest growth over the forecast period due to their broader impact on managing various complications and potentially lower cost.

Within this market, hospital pharmacies is expected to witness the highest growth over the forecast period.

North America will remain the largest region over the forecast period due to increasing incidences of chronic diseases and higher adoption rate of advanced medical technologies in the region.

Features of the Global Eisenmenger Syndrome Treatment Market

Market Size Estimates: Eisenmenger syndrome treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Eisenmenger syndrome treatment market size by drug type, distribution channel, and region in terms of value ($B).

Regional Analysis: Eisenmenger syndrome treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, distribution channels, and regions for the eisenmenger syndrome treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the eisenmenger syndrome treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for eisenmenger syndrome treatment market?

Answer: The global eisenmenger syndrome treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the eisenmenger syndrome treatment market?

Answer: The major drivers for this market are growing number of patients suffering from eisenmenger syndrome and rising focus on r&d activities related to the development of advanced drugs.

Q3. What are the major segments for eisenmenger syndrome treatment market?

Answer: The future of the eisenmenger syndrome treatment market looks promising with opportunities in the hospital pharmacies, online pharmacies, and retail pharmacies markets.

Q4. Who are the key eisenmenger syndrome treatment market companies?

Answer: Some of the key eisenmenger syndrome treatment companies are as follows:

  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Pfizer
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Mylan
  • Bayer

Q5. Which eisenmenger syndrome treatment market segment will be the largest in future?

Answer: Lucintel forecasts that endothelin receptor antagonist is expected to witness the highest growth over the forecast period due to their broader impact on managing various complications and potentially lower cost.

Q6. In eisenmenger syndrome treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing incidences of chronic diseases and higher adoption rate of advanced medical technologies in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the eisenmenger syndrome treatment market by drug type (antiarrhythmic agents, blood thinning agents, endothelin receptor antagonist, and others), distribution channel (hospital pharmacies, online pharmacies, and retail pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Eisenmenger Syndrome Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Eisenmenger Syndrome Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Eisenmenger Syndrome Treatment Market by Drug Type
    • 3.3.1: Antiarrhythmic Agents
    • 3.3.2: Blood Thinning Agents
    • 3.3.3: Endothelin Receptor Antagonist
    • 3.3.4: Others
  • 3.4: Global Eisenmenger Syndrome Treatment Market by Distribution Channel
    • 3.4.1: Hospital Pharmacies
    • 3.4.2: Online Pharmacies
    • 3.4.3: Retail Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Eisenmenger Syndrome Treatment Market by Region
  • 4.2: North American Eisenmenger Syndrome Treatment Market
    • 4.2.1: North American Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
    • 4.2.2: North American Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
  • 4.3: European Eisenmenger Syndrome Treatment Market
    • 4.3.1: European Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
    • 4.3.2: European Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
  • 4.4: APAC Eisenmenger Syndrome Treatment Market
    • 4.4.1: APAC Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
    • 4.4.2: APAC Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
  • 4.5: ROW Eisenmenger Syndrome Treatment Market
    • 4.5.1: ROW Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
    • 4.5.2: ROW Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Eisenmenger Syndrome Treatment Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global Eisenmenger Syndrome Treatment Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Eisenmenger Syndrome Treatment Market by Region
  • 6.2: Emerging Trends in the Global Eisenmenger Syndrome Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Eisenmenger Syndrome Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Eisenmenger Syndrome Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Actelion Pharmaceuticals
  • 7.2: Gilead Sciences
  • 7.3: Pfizer
  • 7.4: Teva Pharmaceutical Industries
  • 7.5: AstraZeneca
  • 7.6: Novartis
  • 7.7: Merck & Co
  • 7.8: GlaxoSmithKline
  • 7.9: Mylan
  • 7.10: Bayer